# data[].attributes.body
http://ec.europa.eu/health/human-use/clinical-trials/developments/index_en.htm

# data[].attributes.attachment_link.readable_text
08/12/2017
Adoption of the Detailed Commission guideline of 8 December 2017 on the good manufacturing practice for investigational medicinal products pursuant to the second paragraph of the Article 63(1) of Regulation (EU) No 536/2014.
The guideline is available here and will become applicable as from the date of entry into application of Regulation (EU) 536/2014.
09/10/2017
Publication in Eudralex - Volume 10: new documents, in view of preparing for entry into application of the Regulation (EU) No 536/2017
New Clinical Trials Expert Group recommendations on Auxiliary medicinal products in clinical trials, Risk proportionate approaches in the clinical trials, Summaries of Clinical Trials Results for Laypersons have been published in Eudralex - Volume 10. Those documents, which are in principle developed in order to prepare for the entry into application of new Clinical Trials Regulation, may be taken into account to the extent possible for in the context of the clinical trials conducted on the basis of Directive 2001/20/EC
16/09/2017
Publication of Commission Delegated Regulation (EU) 2017/1569 of 23 May 2017 supplementing Regulation (EU) No 536/2014 of the European Parliament and of the Council by specifying principles of and guidelines for good manufacturing practice for investigational medicinal products for human use and arrangements for inspections.
The Commission adopted on 23 May 2017 the Commission Delegated Regulation (EU) 2017/1569 (for linguistic versions, click here) supplementing Regulation (EU) 536/2014 of the European Parliament and of the Council by specifying principles and guidelines for good manufacturing practice for investigational medicinal products for human use and arrangements for inspections, which will become applicable at the day of entry into application of Regulation (EU) 536/2014.

07/08/2017
Responses to the public consultation on "Risk proportionate approaches in clinical trials".
A public consultation took place from 1 June 2016 to 31 August 2016 on "Risk proportionate approaches in clinical trials".

A summary of the comments as well as the replies are available here.
07/08/2017
Responses to the public consultation on "Summary of Clinical Trial Results for Laypersons". 07/08/2017
Responses to the public consultation on the revision of the "Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs)" (previously called "Guidance on Investigational Medicinal Products (IMPS) and Non-Investigational Medicinal Products (NIMPs)"). 07/08/2017
Responses to the public consultation on "Ethical Considerations for Clinical Trials on Medicinal products conducted with Minors". 24/03/2017 Adoption of the Commission Implementing Regulation (EU) 2017/556 on the detailed arrangements for the good clinical practice inspection procedures pursuant to Regulation (EU) No 536/2014
A public consultation took place from 1 June 2016 to 31 August 2016 on "Risk proportionate approaches in clinical trials".
09/03/2016
Responses to the public consultation on detailed arrangements for clinical trial inspection procedures including the qualification and training requirements for inspectors pursuant to Article 78(7) of Regulation (EU) No 536/2014.
A summary of the comments as well as the replies are available here.

A public consultation took place from 1 June 2016 to 31 August 2016 on the revision of the "Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs)" (previously called "Guidance on Investigational Medicinal Products (IMPS) and Non-Investigational Medicinal Products (NIMPs)")Risk proportionate approaches in clinical trials".
02/03/2016
Responses to the public consultations on Good Manufacturing Practice for investigational medicinal products.
A summary of the comments as well as the replies are available here.

A public consultation took place from 1 June 2016 to 31 August 2016 on "Ethical Considerations for Clinical Trials on Medicinal products conducted with Minors".
07/05/2014
The new Regulation No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC was published in the Official Journal on 27 May 2014.
A summary of the comments as well as the replies are available here.

The Commission has adopted on 24 of March the Commission Implementing Regulation (EU) 2017/556 on the detailed arrangements for the good clinical practice inspection procedures, required by Regulation (EU) No 536/2014. The Commission Implementing Regulation will enter into application on the day of entry into application of Regulation (EU) No 536/2014.

A public consultation took place from 28 August 2015 to 24 November 2015 on the Commission working document in view of preparing an Implementing Act on the detailed arrangements for GCP inspection procedures including the qualification and training requirements for inspectors.

A summary of the comments as well as the replies are available here.

A public consultation took place from 28 August 2015 to 24 November 2015 on the Commission Delegated Act on principles and guidelines on good manufacturing practice for investigational medicinal products and on inspection procedures. A summary of the comments as well as the replies are available here.

A public consultation took place from 28 August 2015 to 24 November 2015 on the Commission guidelines on good manufacturing practice for investigational medicinal products. A summary of the comments as well as the replies are available here.

23/04/2013
Responses to the public consultation on the template for the qualified person's declaration concerning GMP compliance of investigational medicinal products manufactured in non-EU countries.
07/07/2011
Responses to the public consultation on the concept paper on the Revision of the "Clinical Trials Directive" 2001/20/EC.
A public consultation took place from 6 February 2013 to 2 April 2013 on draft template for the qualified person's declaration concerning GMP compliance of investigational medicinal products manufactured in non-EU countries.

The replies are available here.
14/06/2011
Revision of the "Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3')".
For more information, see EudraLex - Volume 10.

The Commission has adopted, on 17 July 2012, a Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.

12/04/2012
Guidance documents applying to clinical trials - Questions & Answers Document, Version 10.0 (April 2012).

The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 10.0 of this document is available here.

26/08/2011
Guidance documents applying to clinical trials - Questions & Answers Document, Version 9.0 (August 2011).

The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 9.0 of this document is available here.
18/03/2011
Guidance documents applying to clinical trials - Questions & Answers Document, Version 8.0 (March 2011)
A public consultation took place from 9 February 2011 to 13 May 2011 on the concept paper on the Revision of the "Clinical Trials Directive" 2001/20/EC.
18/03/2011
Guidance on investigational medicinal products (IMPs) and "non investigational medicinal products" (NIMPs), rev.1 (March 2011).
A summary of the comments as well as the replies are available here.
14/02/2011
Responses to the public consultation on the "Draft Implementing technical guidance - List of fields for result-related information to be submitted to the 'EudraCT' clinical trials database, and to be made public, in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41 of Regulation (EC) No 1901/2006 and their implementing guidelines 2008/C168/02 and 2009/C28/01".
For the text, see chapter II of EudraLex - Volume 10.

This revision replaces the following three documents:

"Revision 2 of the Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3')";

The "Detailed guidance on the European database of Suspected Unexpected Serious Adverse Reactions (Eudravigilance - Clinical Trial Module)"; and

The "Questions & Answers specific to adverse reaction reporting in clinical trials".

From today, all EU citizens will have access to information on the thousands of authorised pharmaceutical clinical trials that are underway in the EU. The aim of this official public register is to make clinical research on pharmaceuticals more transparent for patients and others and to avoid unnecessary duplication of clinical trials. Every year approximately 4000 clinical trials are authorised in the EU. Since most of them last 2 to 3 years, this means that around 10 000 trials are ongoing at any given time.
09/11/2010
EudraCT - list of additional fields contained in EudraCT (reasons for negative opinions of the Ethics Committee).
Europa - Press releases.

The clinical trials register: https://www.ClinicalTrialsRegister.eu
09/11/2010
Responses to the public consultation on "draft revised version of detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use ('CT-3')".
The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 8.0 of this document is available here.

This is a revision of the Guidance on investigational medicinal products (IMPs) and "non investigational medicinal products" (NIMPs), which had been published in 2007. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NiMPs in the application dossier. This revision completes the detailed guidance CT-1, which sets out the framework of a harmonised dossier requirements in the request for authorisation of a clinical trial to the national competent authority. The document is available here.
30/09/2010
Guidance documents applying to clinical trials - Questions & Answers Document, Version 7.0 (September 2010).
A public consultation took place from 1 June 2010 to 30 September 2010 on the "Draft Implementing technical guidance - List of fields for result-related information to be submitted to the 'EudraCT' clinical trials database, and to be made public, in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41 of Regulation (EC) No 1901/2006 and their implementing guidelines 2008/C168/02 and 2009/C28/01".
22/09/2010
Responses to the public consultation on draft guidance - Harmonised requirements for non-investigational medicinal products in CTA submissions.
The replies are available here.

The ICH guideline E2F gives sponsors guidance as to how to draw up the yearly safety report (Article 17(2) of the "Clinical Trials Directive" 2001/20/EC. To give additional support, ICH has established "model DSURs".
03/09/2010
Important change to the planned production of EudraCT Version 8.0 and the Clinical Trials Application Form.
These "model DSURs" take account of the differing knowledge about a medicine, depending on whether the sponsor holds the marketing authorisation or not.
20/07/2010
Note to Clinical Trials Application Form.
In accordance with point 3.3. of Commission Guidance 2009/C28/01 on the information concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT), where a negative opinion on a clinical trial bas been issued by an Ethics Committee, the information on the trial will be published, together with a field indicating the reason for the negative opinion. This document lists the fields which are going to be contained in EudraCT.

This list is an addendum to the technical guidance on EudraCT contained in EudraLex Volume 10. The document is available here.
01/06/2010
Update of substantial amendment notification form and end of trial notification form.
A public consultation took place from 17 June 2010 to 10 September 2010 on "draft revised version of detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use ('CT-3')".

The replies are available here.
01/06/2010
Guidance documents applying to clinical trials - Questions & Answers Document, Version 6.0 (June 2010)
The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 7.0 of this document is available here.
30/03/2010
Responses to the public consultation paper "Assessment of the functioning of the 'Clinical Trials Directive' 2001/20/EC".
A public consultation took place from 1 June 2010 to 30 September 2010 draft guidance - Harmonised requirements for non-investigational medicinal products in CTA submissions.

The replies are available here.
30/03/2010
Revision of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial (Version of March 2010).
The production of EudraCT Version 8.0 has been delayed. Consequently, Revision 4 dated November 2009 of the Clinical Trials Application Form will not apply for the time being. For more information please refer to the EudraCT website.
30/03/2010
Guidance documents applying to clinical trials - Questions & Answers Document, Version 5.0 (March 2010).
EudraCT Version 8.0 will go into production on 7 September 2010. EudraCT Version 8.0 will use the Clinical Trials Application Form (Annex 1 Revision 4 dated November 2009). Consequently, the Clinical Trials Application Form (Annex 1 Revision 4 dated November 2009) will apply as of 7 September 2010.
30/03/2010
Annex VI to Guidance for the conduct of GCP inspections - Record keeping and archiving of documents (March 2010).
More information is available here.
03/12/2009
Detailed guidelines on good clinical practice specific to advanced therapy medicinal products.
The substantial amendment notification form and end of trial notification form have been aligned to the revised version of the "Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial".

The updated forms are available in EudraLex - Volume 10.

The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 6.0 of this document is available here.
03/12/2009
Questions & Answers specific to adverse reaction reporting in clinical trials.
A public consultation took place from 9 October 2009 to 8 January 2010 on the paper "Assessment of the functioning of the 'Clinical Trials Directive' 2001/20/EC".
10/11/2009
Responses to the Public consultation on draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial.
A summary of the comments as well as the replies are available here.

This Document is available in EudraLex - Volume 10.
09/10/2009
Information for interested parties.
The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 5.0 of this document is available in EudraLex - Volume 10.
28/07/2009
The "Questions and Answers document" in the EudraLex volume 10 on clinical trials has been revised.
This Document is available in EudraLex - Volume 10.
22/06/2009
Request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities and for opinion of the Ethics Committees in the Community - revised application form applicable as of Q4 of 2009.
The EU Regulation 1394/2007 on advanced therapy medicinal products requires the Commission to draw up detailed guidelines on good clinical practice ("GCP") specific to advanced therapy medicinal products ("ATMPs").
22/06/2009
The "Questions and Answers document" in the EudraLex volume 10 on clinical trials has been revised.
These guidelines are published here.
08/06/2009
Guidance for coordination of GCP inspections and co-operation between GCP inspectors, the reference and concerned Member States and CMD(h) , in the context of the evaluation of the GCP compliance of marketing authorization applications for mutual recognition and decentralized procedures has been published today in EudraLex.
These detailed guidelines do not replace but supplement the principles and detailed guidelines set out in Community laws and guidelines. These detailed guidelines specific to ATMPs should be read in conjunction with the existing detailed guidelines on GCP.
13/05/2009
Revision 1 of Guidance for exchange of GCP Inspection Reports according to Article 15(2) of Directive 2001/20/EC has been published today in EudraLex.
This document is published here.
04/02/2009
Guidelines concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT), and on EudraCT information to be made public by the European Medicines Agency have been published today in EudraLex.
A public consultation took place from 22 June 2009 to 8 September 2009 on draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial.
16/12/2008
Guidance documents applying to clinical trials - Publication of "Questions & Answers" Document, Version 2.0 (December 2008).
The replies are available here.
05/11/2008
Publication of additional guidelines on GCP inspections According to Article 29 of the Commission Directive 2005/28/EC laying down principles and detailed guidelines for good clinical practices.
The launch into production of Version 8 of EudraCT, as well as the publication of the protocol-related information contained in EudraCT, have been postponed, for reasons related to IT, to the first half of 2010.
22/10/2008
Responses to the public consultation on the Revised Clinical Trial Application Form as regards advanced therapy investigational medicinal products.
The revised version 4.0 of this document is available here.
21/10/2008
Responses to the public consultation on the data fields contained in the "EudraCT" clinical trials database to be included in the "EudraPharm" database on medicinal products and made public.
Recent changes in the regulatory framework for pharmaceuticals and clinical trials in the EU (mainly consequences of the paediatrics legislation and the legislation on advanced therapies) have required changes to the clinical trials application form. This is the revised version of the clinical trials application form. It will become applicable in the course of Q4 2009, and is published here in advance to allow stakeholders time for preparation. A precise date for applicability is going to be published by the Commission and EMEA in due course and will coincide with the launch into production of Version 8 of EudraCT.
15/10/2008
Responses to the public consultation on draft detailed guideline on good clinical practice specific to advanced therapy medicinal products.
The revised version 3.0 of this document is available here.
13/10/2008
Responses to the public consultation on the data fields of the clinical trials database (EudraCT) and the information on trial results for paediatric clinical trials to be made publicly available.
The text is available here.

The guidelines is available here.

The guidelines are available here.

The Questions and Answers document in the EudraLex chapter on clinical trials has been revised. The version 2.0 of this document is available here.

The Commission shall publish guidance on the conduct of inspections by the competent authorities of the different Member States. Annexes V (Phase I units) and VII (Bioanalytical part, Pharmacokinetic and Statistical Analyses of Bioequivalence Trials) to these guidelines have now been published in EudraLex - Volume 10. Moreover, the Commission has issued Guidelines for the procedure for standardisation of GCP inspection entries in EudraCT. More information is available here.

The replies are available here.

The replies are available here.

The replies are available here.

The replies are available here.

Related information

# data[].attributes.attachment_link.title
Clinical trials - Major developments - Public Health - European Commission

# data[].attributes.attachment_link.description
08/12/2017Adoption of the Detailed Commission guideline of 8 December 2017 on the good manufacturing practice for investigational medicinal products pursuant to the second paragraph of the Article 63(1) of Regulation (EU) No 536/2014. The guideline is available here and will become applicable as from the date of entry into application of Regulation (EU) 536/2014.